Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu, China.
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China.
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189025. doi: 10.1016/j.bbcan.2023.189025. Epub 2023 Nov 20.
Microbes are pivotal in contemporary cancer research, influencing various biological behaviors in cancer. The previous notion that the lung was sterile has been destabilized by the discovery of microbiota in the lower airway and lung, even within tumor tissues. Advances of biotechnology enable the association between intratumor microbiota and lung cancer to be revealed. Nonetheless, the origin and tumorigenicity of intratumor microbiota in lung cancer still remain implicit. Additionally, accumulating evidence indicates that intratumor microbiota might serve as an emerging biomarker for cancer diagnosis, prognosis, and even a therapeutic target across multiple cancer types, including lung cancer. However, research on intratumor microbiota's role in lung cancer is still nascent and warrants more profound exploration. Herein, this paper provides an extensive review of recent advancements in the following fields, including 1) established and emerging biotechnologies utilized to study intratumor microbiota in lung cancer, 2) causation between intratumor microbiota and lung cancer from the perspectives of translocation, cancerogenesis and metastasis, 3) potential application of intratumor microbiota as a novel biomarker for lung cancer diagnosis and prognosis, and 4) promising lung cancer therapies via regulating intratumor microbiota. Moreover, this review addresses the limitations, challenges, and future prospects of studies focused on intratumor microbiota in lung cancer.
微生物在当代癌症研究中起着关键作用,影响着癌症的各种生物学行为。先前认为肺部是无菌的,但在下呼吸道和肺部,甚至在肿瘤组织中发现了微生物群,这一观点已经不再成立。生物技术的进步使人们能够揭示肿瘤内微生物群与肺癌之间的关联。然而,肺癌中肿瘤内微生物群的起源和致瘤性仍然不明确。此外,越来越多的证据表明,肿瘤内微生物群可能作为一种新兴的生物标志物,用于多种癌症类型的癌症诊断、预后,甚至治疗靶点,包括肺癌。然而,关于肿瘤内微生物群在肺癌中的作用的研究还处于起步阶段,需要更深入的探索。本文广泛综述了以下领域的最新进展:1)用于研究肺癌肿瘤内微生物群的现有和新兴生物技术;2)从易位、癌变和转移的角度探讨肿瘤内微生物群与肺癌的因果关系;3)肿瘤内微生物群作为肺癌诊断和预后新型生物标志物的潜在应用;4)通过调节肿瘤内微生物群治疗肺癌的有前途的方法。此外,本文还讨论了肺癌肿瘤内微生物群研究的局限性、挑战和未来前景。